Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ATYR)

aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update

GlobeNewswire March 25, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Benzinga.com March 23, 2019

aTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire March 21, 2019

aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th

GlobeNewswire March 18, 2019

40 Stocks Moving In Monday's Mid-Day Session

Benzinga.com March 11, 2019

aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring

GlobeNewswire March 11, 2019

aTyr Pharma Announces Participation at March Investor Conferences

GlobeNewswire March 4, 2019

aTyr Pharma Presents Compelling Preclinical Data Highlighting Potential of ATYR1923 to Regulate Myeloid Cell Biology During Lung Inflammation

GlobeNewswire February 27, 2019

aTyr Pharma to Present at the BIO CEO & Investor Conference

GlobeNewswire February 5, 2019

aTyr Pharma Announces Research Collaboration with the University of Nebraska Medical Center and Expansion of Successful Pilot Study

GlobeNewswire January 30, 2019

Pangu BioPharma (an aTyr Pharma Subsidiary) and The Hong Kong University of Science and Technology Recognized for Pioneering Work Leading to New Investigational Therapeutic for Lung Disease

GlobeNewswire January 16, 2019

aTyr Pharma Announces Participation at Upcoming San Francisco Investor Events

GlobeNewswire January 2, 2019

aTyr Pharma Announces Initiation of Phase 1b/2a Study of ATYR1923 in Patients with Pulmonary Sarcoidosis and Collaboration with the Foundation for Sarcoidosis Research (FSR)

GlobeNewswire December 4, 2018

aTyr Pharma to Present at the BMO 2018 Prescriptions for Success Healthcare Conference

GlobeNewswire November 28, 2018

Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics — Emerging Consolidated Expectations, Analyst Ratings

GlobeNewswire November 21, 2018

aTyr Pharma Announces Third Quarter 2018 Operating Results and Provides Corporate Update

GlobeNewswire November 13, 2018

aTyr Pharma to Host Conference Call and Webcast of Third Quarter 2018 Financial Results on November 13, 2018

GlobeNewswire November 8, 2018

aTyr Pharma Presents at American Society of Human Genetics 2018 Meeting

GlobeNewswire October 17, 2018

aTyr Pharma Announces Leadership Transition

GlobeNewswire October 15, 2018

aTyr Pharma Announces Pulmonary Sarcoidosis as Disease Indication for Phase 1b/2a Clinical Study and Educational Webinar

GlobeNewswire September 27, 2018